Matthias A Karajannis1, Geneviève Legault1, Michael J Fisher1, Sarah S Milla1, Kenneth J Cohen1, Jeffrey H Wisoff1, David H Harter1, Judith D Goldberg1, Tsivia Hochman1, Amanda Merkelson1, Michael C Bloom1, Angela J Sievert1, Adam C Resnick1, Girish Dhall1, David T W Jones1, Andrey Korshunov1, Stefan M Pfister1, Charles G Eberhart1, David Zagzag1, Jeffrey C Allen1. 1. NYU Comprehensive Neurofibromatosis Center, Division of Pediatric Hematology/Oncology, Department of Pediatrics and Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York (M.A.K., G.L., A.M., J.C.A.); Division of Oncology, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania (M.J.F., A.J.S.); Department of Radiology, NYU Langone Medical Center, New York, New York (S.S.M., M.C.B.); The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland (K.J.C.); Division of Pediatric Neurosurgery, Department of Neurosurgery, NYU Langone Medical Center, New York, New York (J.H.W., D.H.H.); Division of Biostatistics, Department of Population Health and The Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York (J.D.G., T.H.); Department of Neurosurgery, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania (A.C.R); Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California (G.D.); German Cancer Research Center and University Hospital, Heidelberg, Germany (D.T.W.J., A.K., S.M.P.); Division of Neuropathology, Department of Pathology, Johns Hopkins University, Baltimore, Maryland (C.G.E.); Division of Neuropathology, Department of Pathology, Department of Neurosurgery and Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York (D.Z.).
Abstract
BACKGROUND: Activation of the RAS-RAF-MEK-ERK signaling pathway is thought to be the key driver of pediatric low-grade astrocytoma (PLGA) growth. Sorafenib is a multikinase inhibitor targeting BRAF, VEGFR, PDGFR, and c-kit. This multicenter phase II study was conducted to determine the response rate to sorafenib in patients with recurrent or progressive PLGA. METHODS: Key eligibility criteria included age ≥ 2 years, progressive PLGA evaluable on MRI, and at least one prior chemotherapy treatment. Sorafenib was administered twice daily at 200 mg/m(2)/dose (maximum of 400 mg/dose) in continuous 28-day cycles. MRI, including 3-dimensional volumetric tumor analysis, was performed every 12 weeks. BRAF molecular testing was performed on tumor tissue when available. RESULTS: Eleven patients, including 3 with neurofibromatosis type 1 (NF1), were evaluable for response; 5 tested positive for BRAF duplication. Nine patients (82%) came off trial due to radiological tumor progression after 2 or 3 cycles, including 3 patients with confirmed BRAF duplication. Median time to progression was 2.8 months (95% CI, 2.1-31.0 months). Enrollment was terminated early due to this rapid and unexpectedly high progression rate. Tumor tissue obtained from 4 patients after termination of the study showed viable pilocytic or pilomyxoid astrocytoma. CONCLUSIONS: Sorafenib produced unexpected and unprecedented acceleration of tumor growth in children with PLGA, irrespective of NF1 or tumor BRAF status. In vitro studies with sorafenib indicate that this effect is likely related to paradoxical ERK activation. Close monitoring for early tumor progression should be included in trials of novel agents that modulate signal transduction.
BACKGROUND: Activation of the RAS-RAF-MEK-ERK signaling pathway is thought to be the key driver of pediatric low-grade astrocytoma (PLGA) growth. Sorafenib is a multikinase inhibitor targeting BRAF, VEGFR, PDGFR, and c-kit. This multicenter phase II study was conducted to determine the response rate to sorafenib in patients with recurrent or progressive PLGA. METHODS: Key eligibility criteria included age ≥ 2 years, progressive PLGA evaluable on MRI, and at least one prior chemotherapy treatment. Sorafenib was administered twice daily at 200 mg/m(2)/dose (maximum of 400 mg/dose) in continuous 28-day cycles. MRI, including 3-dimensional volumetric tumor analysis, was performed every 12 weeks. BRAF molecular testing was performed on tumor tissue when available. RESULTS: Eleven patients, including 3 with neurofibromatosis type 1 (NF1), were evaluable for response; 5 tested positive for BRAF duplication. Nine patients (82%) came off trial due to radiological tumor progression after 2 or 3 cycles, including 3 patients with confirmed BRAF duplication. Median time to progression was 2.8 months (95% CI, 2.1-31.0 months). Enrollment was terminated early due to this rapid and unexpectedly high progression rate. Tumor tissue obtained from 4 patients after termination of the study showed viable pilocytic or pilomyxoid astrocytoma. CONCLUSIONS:Sorafenib produced unexpected and unprecedented acceleration of tumor growth in children with PLGA, irrespective of NF1 or tumorBRAF status. In vitro studies with sorafenib indicate that this effect is likely related to paradoxical ERK activation. Close monitoring for early tumor progression should be included in trials of novel agents that modulate signal transduction.
Authors: Joann L Ater; Tianni Zhou; Emiko Holmes; Claire M Mazewski; Timothy N Booth; David R Freyer; Ken H Lazarus; Roger J Packer; Michael Prados; Richard Sposto; Gilbert Vezina; Jeffrey H Wisoff; Ian F Pollack Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: Eugene I Hwang; Regina I Jakacki; Michael J Fisher; Lindsay B Kilburn; Marianna Horn; Gilbert Vezina; Brian R Rood; Roger J Packer Journal: Pediatr Blood Cancer Date: 2012-09-13 Impact factor: 3.167
Authors: Angela J Sievert; Shih-Shan Lang; Katie L Boucher; Peter J Madsen; Erin Slaunwhite; Namrata Choudhari; Meghan Kellet; Phillip B Storm; Adam C Resnick Journal: Proc Natl Acad Sci U S A Date: 2013-03-26 Impact factor: 11.205
Authors: AeRang Kim; Eva Dombi; Kathleen Tepas; Elizabeth Fox; Staci Martin; Pamela Wolters; Frank M Balis; Nalini Jayaprakash; Baris Turkbey; Naira Muradyan; Peter L Choyke; Alyssa Reddy; Bruce Korf; Brigitte C Widemann Journal: Pediatr Blood Cancer Date: 2012-09-07 Impact factor: 3.167
Authors: Thomas Botton; Iwei Yeh; Tyrrell Nelson; Swapna S Vemula; Alyssa Sparatta; Maria C Garrido; Maryline Allegra; Stephane Rocchi; Philippe Bahadoran; Timothy H McCalmont; Philip E LeBoit; Elizabeth A Burton; Gideon Bollag; Robert Ballotti; Boris C Bastian Journal: Pigment Cell Melanoma Res Date: 2013-08-19 Impact factor: 4.693
Authors: David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister Journal: Nat Genet Date: 2013-06-30 Impact factor: 38.330
Authors: Georgia Hatzivassiliou; Jacob R Haling; Huifen Chen; Kyung Song; Steve Price; Robert Heald; Joanne F M Hewitt; Mark Zak; Ariana Peck; Christine Orr; Mark Merchant; Klaus P Hoeflich; Jocelyn Chan; Shiuh-Ming Luoh; Daniel J Anderson; Mary J C Ludlam; Christian Wiesmann; Mark Ultsch; Lori S Friedman; Shiva Malek; Marcia Belvin Journal: Nature Date: 2013-08-11 Impact factor: 49.962
Authors: Jinghui Zhang; Gang Wu; Claudia P Miller; Ruth G Tatevossian; James D Dalton; Bo Tang; Wilda Orisme; Chandanamali Punchihewa; Matthew Parker; Ibrahim Qaddoumi; Fredrick A Boop; Charles Lu; Cyriac Kandoth; Li Ding; Ryan Lee; Robert Huether; Xiang Chen; Erin Hedlund; Panduka Nagahawatte; Michael Rusch; Kristy Boggs; Jinjun Cheng; Jared Becksfort; Jing Ma; Guangchun Song; Yongjin Li; Lei Wei; Jianmin Wang; Sheila Shurtleff; John Easton; David Zhao; Robert S Fulton; Lucinda L Fulton; David J Dooling; Bhavin Vadodaria; Heather L Mulder; Chunlao Tang; Kerri Ochoa; Charles G Mullighan; Amar Gajjar; Richard Kriwacki; Denise Sheer; Richard J Gilbertson; Elaine R Mardis; Richard K Wilson; James R Downing; Suzanne J Baker; David W Ellison Journal: Nat Genet Date: 2013-04-14 Impact factor: 38.330
Authors: Huat C Lim; Meagan Montesion; Thomas Botton; Eric A Collisson; Sarah E Umetsu; Spencer C Behr; John D Gordan; Phil J Stephens; Robin K Kelley Journal: Oncologist Date: 2018-04-05
Authors: Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Anuradha Banerjee; Roger J Packer; Lindsay B Kilburn; Stewart Goldman; Ian F Pollack; Ibrahim Qaddoumi; Regina I Jakacki; Paul G Fisher; Girish Dhall; Patricia Baxter; Susan G Kreissman; Clinton F Stewart; David T W Jones; Stefan M Pfister; Gilbert Vezina; Jessica S Stern; Ashok Panigrahy; Zoltan Patay; Benita Tamrazi; Jeremy Y Jones; Sofia S Haque; David S Enterline; Soonmee Cha; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi Journal: Lancet Oncol Date: 2019-05-28 Impact factor: 41.316